Vaccine Development Against Trypanosoma cruzi and Chagas Disease

Juan C. Vázquez-Chagoyán, Shivali Gupta, Nisha Jain Garg

Research output: Chapter in Book/Report/Conference proceedingChapter

46 Scopus citations


The pathology of Chagas disease presents a complicated and diverse picture in humans. The major complications and destructive evolutionary outcomes of chronic infection by Trypanosoma cruzi in humans include ventricular fibrillation, thromboembolism and congestive heart failure. Studies in animal models and human patients have revealed the pathogenic mechanisms during disease progression, pathology of disease and features of protective immunity. Accordingly, several antigens, antigen-delivery vehicles and adjuvants have been tested to elicit immune protection to T. cruzi in experimental animals. This review summarizes the research efforts in vaccine development against Chagas disease during the past decade.

Original languageEnglish (US)
Title of host publicationAdvances in Parasitology
PublisherAcademic Press
Number of pages26
StatePublished - 2011

Publication series

NameAdvances in Parasitology
ISSN (Print)0065-308X


  • Adjuvants
  • Chagas
  • Immunity
  • Therapeutic and prophylactic vaccine
  • Trypanosoma cruzi

ASJC Scopus subject areas

  • Parasitology


Dive into the research topics of 'Vaccine Development Against Trypanosoma cruzi and Chagas Disease'. Together they form a unique fingerprint.

Cite this